Decreased ARG1 expression as an adverse prognostic phenotype in non-alcoholic non-virus-related hepatocellular carcinoma.
ARG1
Biliary/progenitor cell markers
Non-alcoholic non-virus-related hepatocellular carcinoma
Prognosis
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
26
11
2021
accepted:
26
03
2022
revised:
21
02
2022
pubmed:
24
4
2022
medline:
4
8
2022
entrez:
23
4
2022
Statut:
ppublish
Résumé
The incidence of non-alcoholic non-virus-related hepatocellular carcinoma (NANV-HCC) is increasing along with the growing prevalence of metabolic disorders. In this subset, few useful biomarkers are available to narrow down the high-risk group for recurrence. This study aimed to evaluate the prognostic impact of decreased ARG1 (arginase-1), which is pathologically known as a marker reflecting hepatocyte differentiation, in NANV-HCC. Besides, its relationship with biliary/progenitor cell markers, whose expressions are associated with poor prognosis, was also assessed. To reveal the clinicopathological association of decreased ARG1 expression in NANV-HCC, we investigated 99 patients who underwent curative-intent hepatectomy for NANV-HCC. Tissue microarrays were employed for immunohistochemical analysis. A total of 21 NANV-HCC cases (21%; 21/99) showed decreased ARG1 expression. Decreased ARG1 expression was an independent prognostic factor for both poor DFS (hazard ratio 2.17; 95% confidence interval 1.15-4.09; p = 0.02) and OS (hazard ratio 4.09; 95% confidence interval 1.71-9.80; p = 0.002). In addition, decreased ARG1 expression was significantly associated with expressions of biliary/progenitor cell markers, CK19 and CD56 (p < 0.01). As cytologic features of tumor cells, decreased ARG1 expression was significantly associated with lipid-less cytologic morphology (p = 0.045). These findings indicate that decreased ARG1 expression is a predictive phenotype of postoperative recurrence with poor prognosis in patients with NANV-HCC. Decreased ARG1 expression may be a precursor or overlapping feature with biliary/progenitor cell marker expressions in NANV-HCC.
Identifiants
pubmed: 35459975
doi: 10.1007/s00428-022-03318-3
pii: 10.1007/s00428-022-03318-3
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
253-263Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Sung H, Ferlay J, Laversanne SRL, Soerjomataram M, Jemal I, Bray A, F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660
doi: 10.3322/caac.21660
pubmed: 33538338
Huang DQ, El-Serag HB, Loomba R (2020) Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 18:223–238. https://doi.org/10.1038/s41575-020-00381-6
doi: 10.1038/s41575-020-00381-6
pubmed: 33349658
pmcid: 8016738
Itamoto T, Nakahara H, Amano H, Kohashi T, Ohdan H, Tashiro H, Asahara T (2007) Repeat hepatectomy for recurrent hepatocellular carcinoma. Surgery 141:589–597. https://doi.org/10.1016/j.surg.2006.12.014
doi: 10.1016/j.surg.2006.12.014
pubmed: 17462458
Minagawa M, Makuuchi M, Takayama T, Kokudo N (2003) Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg 238:703–710. https://doi.org/10.1097/01.sla.0000094549.11754.e6
doi: 10.1097/01.sla.0000094549.11754.e6
pubmed: 14578733
pmcid: 1356149
Multhaupt H, Fritz P, Schumacher K (1987) Immunohistochemical localisation of arginase in human liver using monoclonal antibodies against human liver arginase. Histochem 87:465–470. https://doi.org/10.1007/BF00496818
doi: 10.1007/BF00496818
Yan BC, Gong C, Song J, Krausz T, Tretiakova M, Hyjek E, Al-Ahmadie H, Alves V, Xiao SY, Anders RA, Hart JA (2010) Arginase-1 a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol 34:1147–1154. https://doi.org/10.1097/PAS.0b013e3181e5dffa
doi: 10.1097/PAS.0b013e3181e5dffa
pubmed: 20661013
pmcid: 3160135
Radwan NA, Ahmed NS (2012) The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1. Diagn Pathol 7:149. https://doi.org/10.1186/1746-1596-7-149
doi: 10.1186/1746-1596-7-149
pubmed: 23111165
pmcid: 3500209
Mao H, Gao W, Lu G, Fang F, Teng L (2013) Clinicopathological and prognostic implications of arginase expression in hepatocellular carcinoma. Clin Lab 59:37–43
doi: 10.7754/Clin.Lab.2012.120210
You J, Chen W, Chen J, Zheng Q, Dong J, Zhu Y (2018) The oncogenic role of ARG1 in progression and metastasis of hepatocellular carcinoma. Biomed Res Int 2018:2109865. https://doi.org/10.1155/2018/2109865
doi: 10.1155/2018/2109865
pubmed: 30320132
pmcid: 6167590
Obiorah IE, Chahine J, Ko K, Park BU, deGuzman J, Kallakury B (2019) Prognostic implications of arginase and cytokeratin 19 expression in hepatocellular carcinoma after curative hepatectomy correlation with recurrence-free survival. Gastroenterol Res 12:78–87. https://doi.org/10.14740/gr1156
doi: 10.14740/gr1156
Kakehashi A, Suzuki S, Ishii N, Okuno T, Kuwae Y, Fujioka M, Gi M, Stefanov V, Wanibuchi H (2020) Accumulation of 8-hydroxydeoxyguanosine, L-arginine and glucose metabolites by liver tumor cells are the important characteristic features of metabolic syndrome and non-alcoholic steatohepatitis-associated hepatocarcinogenesis. Int J Mol Sci 21:7746. https://doi.org/10.3390/ijms21207746
doi: 10.3390/ijms21207746
pmcid: 7594076
Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H, Tanaka S, Kaneda K, Hirohashi K (2003) Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 94:851–857. https://doi.org/10.1111/j.1349-7006.2003.tb01366.x
doi: 10.1111/j.1349-7006.2003.tb01366.x
pubmed: 14556657
Ding SJ, Li Y, Tan YX, Jiang MR, Tian B, Liu YK, Shao XX, Ye SL, Wu JR, Zeng R, Wang HY, Tang ZY, Xia QC (2004) From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics 3:73–81. https://doi.org/10.1074/mcp.M300094-MCP200
doi: 10.1074/mcp.M300094-MCP200
pubmed: 14593079
Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, Lesaffre E, Libbrecht L, Desmet V, Roskams T (2006) The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin Histopathol 49:138–151. https://doi.org/10.1111/j.1365-2559.2006.02468.x
doi: 10.1111/j.1365-2559.2006.02468.x
Yang XR, Xu Y, Shi GM, Fan J, Zhou J, Ji Y, Sun HC, Qiu SJ, Yu B, Gao Q, He YZ, Qin WZ, Chen RX, Yang GH, Wu B, Lu Q, Wu ZQ, Tang ZY (2008) Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. Clin Cancer Res 14(3850):3859. https://doi.org/10.1158/1078-0432.CCR-07-4338
doi: 10.1158/1078-0432.CCR-07-4338
Kim H, Choi GH, Na DC, Ahn EY, Kim GI, Lee JE, Cho JY, Yoo JE, Choi JS, Park YN (2011) Human hepatocellular carcinomas with “Stemness”-related marker expression: keratin 19 expression and a poor prognosis. Hepatology 541707:1717. https://doi.org/10.1002/hep.24559
doi: 10.1002/hep.24559
Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY (1996) Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers Clinical and biological implications. Am J Pathol 149:1167–1175
pubmed: 8863666
pmcid: 1865193
Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi GM, Zhang BH, Wu WZ, Shi YH, Wu B, Yang GH, Ji Y, Fan J (2010) High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 59:953–962. https://doi.org/10.1136/gut.2008.176271
doi: 10.1136/gut.2008.176271
pubmed: 20442200
Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP (2017) The Eighth Edition AJCC Cancer Staging Manual continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 67:93–99. https://doi.org/10.3322/caac.21388
doi: 10.3322/caac.21388
pubmed: 28094848
Shigematsu Y, Inamura K, Yamamoto N, Mise Y, Saiura A, Ishikawa Y, Takahashi S, Kanda H (2018) Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis. BMC Cancer 18:980. https://doi.org/10.1186/s12885-018-4902-8
doi: 10.1186/s12885-018-4902-8
pubmed: 30326864
pmcid: 6192098
Bosman FT, Carneiro F, Hruban RH, Theise ND (2010) WHO Classification of Tumours of the Digestive System, 4th edn. IARC press, Lyon, France
Kudo M, Kitano M, Sakurai T, Nishida N (2015) General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines: the outstanding achievements of the liver cancer study group of Japan. Dig Dis 33:765–770. https://doi.org/10.1159/000439101
doi: 10.1159/000439101
pubmed: 26488173
Shibahara J, Ando S, Sakamoto Y, Kokudo N, Fukayama M (2014) Hepatocellular carcinoma with steatohepatitic features: a clinicopathological study of Japanese patients. Histopathology 64:951–962. https://doi.org/10.1111/his.12343
doi: 10.1111/his.12343
pubmed: 24898917
Shigematsu Y, Kanda H, Amori G, Takahashi Y, Takazawa Y, Inamura K (2022) Nonalcoholic non-virus-related hepatocellular carcinoma arising from nonsteatotic liver: clinical and pathological features. Medicine (Baltimore) 101:e28746. https://doi.org/10.1097/MD.0000000000028746
doi: 10.1097/MD.0000000000028746
Kleiner DE Brunt EM Van Natta M Behling C Contos MJ Cummings OW Ferrell LD Liu YC Torbenson MS Unalp-Arida A Yeh M McCullough AJ Sanyal AJ Nonalcoholic Steatohepatitis Clinical Research N 2005 Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatol 41 1313 1321 https://doi.org/10.1002/hep.20701
Brunt EM (2000) Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatol 31:241–246. https://doi.org/10.1002/hep.510310136
doi: 10.1002/hep.510310136
Tateishi R, Uchino K, Fujiwara N, Takehara T, Okanoue T, Seike M, Yoshiji H, Yatsuhashi H, Shimizu M, Torimura T, Moriyama M, Sakaida I, Okada H, Chiba T, Chuma M, Nakao K, Isomoto H, Sasaki Y, Kaneko S, Masaki T, Chayama K, Koike K (2019) A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update. J Gastroenterol 54:367–376. https://doi.org/10.1007/s00535-018-1532-5
doi: 10.1007/s00535-018-1532-5
pubmed: 30498904
Chan AW, Tong JH, Chan SL, Lai PB, To KF (2014) Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma. Histopathology 64:935–950. https://doi.org/10.1111/his.12342
doi: 10.1111/his.12342
pubmed: 24506513
Brunt EM, Paradis V, Sempoux C, Theise ND (2015) Biphenotypic (hepatobiliary) primary liver carcinomas: the work in progress. Hepat Oncol 2:255–273. https://doi.org/10.2217/hep.15.8
doi: 10.2217/hep.15.8
pubmed: 30191007
pmcid: 6095308
Govaere O, Komuta M, Berkers J, Spee B, Janssen C, de Luca F, Katoonizadeh A, Wouters J, van Kempen LC, Durnez A, Verslype C, De Kock J, Rogiers V, van Grunsven LA, Topal B, Pirenne J, Vankelecom H, Nevens F, van den Oord J, Pinzani M, Roskams T (2014) Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut 63:674–685. https://doi.org/10.1136/gutjnl-2012-304351
doi: 10.1136/gutjnl-2012-304351
pubmed: 23958557
Salomao M, Yu WM, Brown RS Jr, Emond JC, Lefkowitch JH (2010) Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol 34:1630–1636. https://doi.org/10.1097/PAS.0b013e3181f31caa
doi: 10.1097/PAS.0b013e3181f31caa
pubmed: 20975341
Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, Bedossa P, Belghiti J (2009) Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 49:851–859. https://doi.org/10.1002/hep.22734
doi: 10.1002/hep.22734
pubmed: 19115377
Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M (2019) From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol 16:411–428. https://doi.org/10.1038/s41575-019-0145-7
doi: 10.1038/s41575-019-0145-7
pubmed: 31028350
Sasaki K, Shindoh J, Margonis GA, Nishioka Y, Andreatos N, Sekine A, Hashimoto M, Pawlik TM (2017) Effect of background liver cirrhosis on outcomes of hepatectomy for hepatocellular carcinoma. JAMA Surg 152:e165059. https://doi.org/10.1001/jamasurg.2016.5059
doi: 10.1001/jamasurg.2016.5059
pubmed: 28052155
Sia D, Villanueva A, Friedman SL, Llovet JM (2017) Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterol 152:745–761. https://doi.org/10.1053/j.gastro.2016.11.048
doi: 10.1053/j.gastro.2016.11.048
Tsui YM, Chan LK, Ng IO (2020) Cancer stemness in hepatocellular carcinoma: mechanisms and translational potential. Br J Cancer 122:1428–1440. https://doi.org/10.1038/s41416-020-0823-9
doi: 10.1038/s41416-020-0823-9
pubmed: 32231294
pmcid: 7217836
Roskams T (2006) Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 25:3818–3822. https://doi.org/10.1038/sj.onc.1209558
doi: 10.1038/sj.onc.1209558
pubmed: 16799623
Uenishi T, Kubo S, Hirohashi K, Yamamoto T, Ogawa M, Tanaka H, Shuto T, Kinoshita H (2002) Expression of bile duct-type cytokeratin in hepatocellular carcinoma in patients with hepatitis C virus and prior hepatitis B virus infection. Cancer Lett 178:107–112. https://doi.org/10.1016/s0304-3835(01)00813-8
doi: 10.1016/s0304-3835(01)00813-8
pubmed: 11849748
Tarlow BD, Pelz C, Naugler WE, Wakefield L, Wilson EM, Finegold MJ, Grompe M (2014) Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes. Cell Stem Cell 15:605–618. https://doi.org/10.1016/j.stem.2014.09.008
doi: 10.1016/j.stem.2014.09.008
pubmed: 25312494
pmcid: 4254170
Chen Y, Wong PP, Sjeklocha L, Steer CJ, Sahin MB (2012) Mature hepatocytes exhibit unexpected plasticity by direct dedifferentiation into liver progenitor cells in culture. Hepatology 55:563–574. https://doi.org/10.1002/hep.24712
doi: 10.1002/hep.24712
pubmed: 21953633
Beaufrere A, Calderaro J, Paradis V (2021) Combined hepatocellular-cholangiocarcinoma: an update. J Hepatol 74:1212–1224. https://doi.org/10.1016/j.jhep.2021.01.035
doi: 10.1016/j.jhep.2021.01.035
pubmed: 33545267
Xue R, Chen L, Zhang C, Fujita M, Li R, Yan SM, Ong CK, Liao X, Gao Q, Sasagawa S, Li Y, Wang J, Guo H, Huang QT, Zhong Q, Tan J, Qi L, Gong W, Hong Z, Li M, Zhao J, Peng T, Lu Y, Lim KHT, Boot A, Ono A, Chayama K, Zhang Z, Rozen SG, Teh BT, Wang XW, Nakagawa H, Zeng MS, Bai F, Zhang N (2019) Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes. Cancer Cell 35932:947-e938. https://doi.org/10.1016/j.ccell.2019.04.007
doi: 10.1016/j.ccell.2019.04.007
Wang AQ, Zheng YC, Du J, Zhu CP, Huang HC, Wang SS, Wu LC, Wan XS, Zhang HH, Miao RY, Sang XT, Zhao HT (2016) Combined hepatocellular cholangiocarcinoma: controversies to be addressed. World J Gastroenterol 22:4459–4465. https://doi.org/10.3748/wjg.v22.i18.4459
doi: 10.3748/wjg.v22.i18.4459
pubmed: 27182157
pmcid: 4858629